Gossamer Bio, Inc. (NASDAQ:GOSS) has been given an average rating of “Buy” by the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $22.80.
A number of equities research analysts recently commented on GOSS shares. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price (up previously from $15.00) on shares of Gossamer Bio in a research report on Thursday, December 17th. Zacks Investment Research lowered Gossamer Bio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 12th.
Several hedge funds have recently made changes to their positions in GOSS. FMR LLC acquired a new position in shares of Gossamer Bio during the 1st quarter worth approximately $26,576,000. Dowling & Yahnke LLC acquired a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $131,000. Cutler Group LP acquired a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $31,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $181,000. Finally, BNP Paribas Arbitrage SA raised its stake in Gossamer Bio by 152.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 13,319 shares of the company’s stock valued at $165,000 after purchasing an additional 8,045 shares during the last quarter. 71.96% of the stock is owned by institutional investors and hedge funds.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial.
See Also: Closed-End Mutual Funds
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.